Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer
The anti-programmed cell death receptor 1 (anti-PD-1) immunotherapy has been recommended in several treatment scenarios of metastatic urothelial cancer (UC), including as a maintenance therapy after first-line chemotherapy. However, the PD-1 inhibitor accelerates tumor growth occasionally, causing h...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2021-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_ad4cde4af837453a8e4b5e6d77c30fb8 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Yangchun Gu |e author |
| 700 | 1 | 0 | |a Huiying He |e author |
| 700 | 1 | 0 | |a Mopei Wang |e author |
| 245 | 0 | 0 | |a Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer |
| 260 | |b Elsevier, |c 2021-01-01T00:00:00Z. | ||
| 500 | |a 2347-5625 | ||
| 500 | |a 2349-6673 | ||
| 500 | |a 10.4103/apjon.apjon-2142 | ||
| 520 | |a The anti-programmed cell death receptor 1 (anti-PD-1) immunotherapy has been recommended in several treatment scenarios of metastatic urothelial cancer (UC), including as a maintenance therapy after first-line chemotherapy. However, the PD-1 inhibitor accelerates tumor growth occasionally, causing hyperprogressive disease (HPD). We presented here a case of HPD in a 43-year-old male Chinese patient with bladder UC, metastasizing to liver and bone, and harboring amplification of Murine Double Minute gene 2, cyclin-dependent kinase 4, fibroblast growth factor receptor substrate 2, ERBB3, and Enhancer of Zeste Homolog 2. After achieving partial remission with the traditional platinum doublet chemotherapy, he sought PD-1 inhibitor (pembrolizumab) for maintenance therapy in another hospital. After 3 doses of pembrolizumab in <2 months, his liver metastasis dramatically increased both in size and number. Liver biopsy confirmed genuine progression. He died from liver failure 6 months later. This case alerted us about HPD again in the scenario of maintenance therapy, enhanced the importance of selecting appropriate patients. | ||
| 546 | |a EN | ||
| 690 | |a bladder urothelial cancer | ||
| 690 | |a hyperprogressive disease | ||
| 690 | |a immunotherapy | ||
| 690 | |a maintenance therapy | ||
| 690 | |a murine double minute gene 2 | ||
| 690 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | ||
| 690 | |a RC254-282 | ||
| 690 | |a Nursing | ||
| 690 | |a RT1-120 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Asia-Pacific Journal of Oncology Nursing, Vol 8, Iss 5, Pp 586-590 (2021) | |
| 787 | 0 | |n http://www.apjon.org/article.asp?issn=2347-5625;year=2021;volume=8;issue=5;spage=586;epage=590;aulast=Gu | |
| 787 | 0 | |n https://doaj.org/toc/2347-5625 | |
| 787 | 0 | |n https://doaj.org/toc/2349-6673 | |
| 856 | 4 | 1 | |u https://doaj.org/article/ad4cde4af837453a8e4b5e6d77c30fb8 |z Connect to this object online. |